Webcast ImageWebcast
Clovis Oncology, Inc. at the Stifel 2017 Healthcare Conference (Replay)
11/15/17 at 9:30 a.m. ET
Clovis Oncology, Inc. at the Stifel 2017 Healthcare Conference
Wednesday, November 15, 2017 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 1.24 (1.98%)
Intraday High$64.41
Intraday Low$62.50
Data as of 12/13/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
12/05/17Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
Clovis seeks U.S. approval for rucaparib as maintenance therapy for women with recurrent ovarian cancer who are platinum sensitive, and in complete or partial response to platinum chemotherapy, with no requirement for diagnostic testing Priority review granted based on positive data from phase 3 ARIEL3 clinical trial in which rucaparib significantly improved PFS in all ovarian cancer patient populations studied ... 
Printer Friendly Version 
11/08/17Clovis Oncology to Present at the Stifel 2017 Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Nov. 8, 2017-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 9:30 AM Eastern Time. The conference will be held at the Lotte New York Palace Hotel in New York City. A live webcast of the presentation can be accessed through the investor relations ... 
Printer Friendly VersionDownload PDF
11/01/17Clovis Oncology Announces Third Quarter 2017 Operating Results
Strong third quarter of launch for Rubraca® (rucaparib) in U.S. with $16.8M reported in net sales An additional $4.4M in commercial value was provided as free drug through our patient assistance program Submission of a supplemental New Drug Application (sNDA) for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer complet... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.